HomeAI · summaries
Storia in 5 fonti
Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1. < | Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
- ·
endpoints.news
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.
